Oral Cannabidiol for Tobacco Cessation
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorJohns Hopkins University
About this trial
Cannabidiol is a compound found in cannabis plants that is well tolerated, has low abuse liability, and might be an effective medication to promote tobacco cessation. This clinical study will use a validated approach for screening tobacco cessation medications to determine if oral cannabidiol increases short-term tobacco abstinence, and evaluate mechanisms that might explain how cannabidiol alters smoking behavior. Results from this study will provide data on the therapeutic potential of cannabidiol for tobacco cessation.
Eligibility criteria
Qualifiers
Have provided written informed consent
Be between the ages of 18 and 65
Report use of > 10 cigarettes per day for > 1 year with smoking status verified by either a positive breath carbon monoxide test (>8ppm) or urine cotinine test (>200ng/mL) at screening
Report interest in quitting tobacco in the next two months
Disqualifiers
Meet Diagnostic and Statistical Manual-V criteria for substance use disorders except for nicotine or tobacco use disorders
Are currently receiving or interested in immediately receiving behavioral treatment or medication for smoking cessation
Test positive for drugs of abuse (except nicotine) and/or breath alcohol test at study admission
Have a current physical or mental illness judged by the study team to negatively impact participant safety or scientific integrity.
Trial design
Treatments tested in this trial
- 300 mg Cannabidiol
- 600 mg Cannabidiol
- Placebo
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Johns Hopkins University
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov